newsfilter
← Earnings
Earnings Releases·

Evolent Health — Third Quarter 2026 Earnings Summary

  • Q3 2026 revenue reached $725.4 million, a 51% year-over-year increase from $479.5 million, while net loss narrowed to $23.6 million from $26.9 million; however, Adjusted EBITDA declined to $34.3 million from $39.0 million and the medical expense ratio rose to 93.0% from 85.0%.
  • The company raised its full-year 2026 Adjusted EBITDA guidance to $130.0–$135.0 million while reiterating revenue guidance of $2.6–$2.7 billion, driven by AI platforms and oncology solutions.
  • Strategic growth was supported by renewing its largest Surgical Management contract for four years and expanding oncology services to add approximately 1 million commercial lives and 11 additional states for a national payer.
  • Capital allocation plans include $26–$28 million in capitalized expenditures and up to $50 million toward reducing outstanding indebtedness by year-end, with no intention to pay cash dividends.
Company
EVOLENT HEALTH INC
Sector
Healthcare
Industry
Health Information Services